On the stock market since 1993, it operates in the world of health and science. It has 609 employees. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
Average growth of 56% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
The cash pile is strong; debt and other items pull the grade toward the middle.
The price isn’t cheap next to earnings — that’s why this grade sits in the middle.
Sales are growing strongly for its sector.
The stock has been running stronger than the market lately.
Business Quality: Profit power and business quality trail similar companies in the sector.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
The stock trades 38% below its peak. The market has trimmed its expectations for the company.
Over the last 3 years, sales grew about 51% a year on average.
The company sells $829.4M a year; the problem isn’t sales — it’s costs running above that number.
There is $919.4M in the vault; even if every debt were paid off, $553.1M would remain.
A loss of $1.6M against $829.4M in annual sales.
Over the last 12 months, executives reported 79 sells against just 13 buys. Not an alarm bell by itself, but a number worth watching.
On our five-subject report card, ARWR sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: ARWR has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (51/100) says the stock isn’t cheap.